In our study, however, the comparison of analysis with and without adjustment for use of hormonal contraception and postmenopausal hormone therapy did not support this hypothesis, since an association of high baseline BMI and weight gain with postmenopausal breast cancer risk was consistently seen in carriers of a pathogenic variant in BRCA1, but not in BRCA2. Here, BRCA2 is linked to breast carcinoma.